Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-lnfected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors

Morbidity and Mortality Weekly Report

Volumn 49, Issue 9, 2000, Pages 185-189

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RIFABUTIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

AIDS RELATED COMPLEX; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRACTICE GUIDELINE; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; HIV INFECTIONS; HUMANS; RIFABUTIN; RIFAMPIN; TUBERCULOSIS;

EID: 0034628927     PISSN: 01492195     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. CDC. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998;47(no. RR-20).
2. Glaxo Wellcome Inc. Abacavir package insert. Research Triangle Park, North Carolina: Glaxo Wellcome Inc., 1998.
3. Benedek IH, Joshi A, Fiske WD, et al. Pharmacokinetic interaction between efavirenz and rifampin in healthy volunteers [Abstract]. In: Program and abstracts of the 12th World AIDS Conference, Geneva, Switzerland, 1998.
4. Abbott Laboratories. Norvir package insert. Chicago, Illinois: Abbott Laboratories, 1999.
5. Veldkamp AI, Hoetelmans MW, Beijnen JH, Mulder JW, Meenhorst PL Ritonavir enables combined therapy with rifampin and saquinavir. Clin Infect Dis 1999;29:1586.
6. Gallicano K, Khaliq Y, Seguin I, et al. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in HIV patients [Abstract]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, 2000.
7. Benedek IH, Fiske WD, White SJ, Stevenson D, Joseph JL, Kornhauser DM. Pharmacokinetic interaction between multiple doses of efavirenz and rifabutin in healthy volunteers [Abstract]. In: Program and abstracts of the 36th Annual Meeting of the Infectious Disease Society of America, Denver, Colorado, 1998.
8. Dietrich MA, Butts JD, Raasch RH. HIV-1 protease inhibitors: a review. Infect Med 1999;16:716-38.
9. Jorga K, Buss NE. Pharmacokinetic drug interaction with saquinavir soft gelatin capsule [Abstract]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 1999.
10. American Thoracic Society/CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000 (in press).